Effect of enoxaparin on peak and trough levels of antifactor Xa in patients with a creatinine clearance of less than 30 mL/min

International Journal of Angiology

Volumn 18, Issue 4, 2009, Pages 184-186

  Sule, Ashish Anil ^a   Tay, Jam Chin ^a   Arul, Earnest ^a  

^a TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

Antifactor Xa; Creatinine clearance; Enoxaparin; Peak; Trough

Indexed keywords

BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTICOAGULATION; ARTICLE; CHINESE; CLINICAL ARTICLE; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DEMOGRAPHY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INDIAN; MALAYSIA; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PRIORITY JOURNAL;

EID: 80053024358     PISSN: 10611711     EISSN: 16155939     Source Type: Journal    
DOI: 10.1055/s-0031-1278351     Document Type: Article

References (11)

1. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
2. Lim MD, Francesco D, John WE, et al. Meta-analysis: Low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006;144:673-84.
3. Benjamin G, Nicolas S, Jerome JS, et al. Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. Nephrol Dial Transplant 2003;18:2348-53.
4. Michael WK, Jeremy JL. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment. Am Heart J 2004;148:582-9.
5. Adam JD, Michael JP, Serdar HU, et al. Antithrombotic therapy and pregnancy: Consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol 2007;457:e1-21.
6. Gailani D, Renne T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vasc Biol 2007;27:2507-13. (Pubitemid 350158899)
7. Green B, Greenwood M, Saltissi D, et al. Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes. Br J Clin Pharmacol 2004;59:281-90.
8. Klingel R, Schaefer M, Schwarting A, et al. Comparative analysis of procoagulatory activity of haemodialysis, haemofiltration and haemodiafiltration with a polysulfone membrane (APS) and with different modes of enoxaparin anticoagulation. Nephrol Dial Transplant 2004;19:164-70. (Pubitemid 38072628)
9. Bruno R, Baille P, Retout S, et al. Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction. Br J Clin Pharmacol 2003;56:407-14. (Pubitemid 37188135)
10. Bazineta A, Almanrica K, Bruneta C, et al. Dosage of enoxaparin among obese and renal impairment patients. Thromb Res 2005;116:41-50.
11. Dinwoodey DL, Ansell JE. Heparins, low-molecular-weight heparins, and pentasaccharides. Clin Geriatr Med 2006;22:1-15. (Pubitemid 41827955)